Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231166 · ClinicalTrials.gov registry record · Phase 1
Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00231166 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT00231166, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with Multiple Myeloma who are relapsed after receiving prior treatment.
Interventions
- DRUG HCD122
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00231166
The ClinicalTrials.gov registry entry for NCT00231166 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HCD122 is the first listed.
NCT00231166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00231166 about?
NCT00231166 is a clinical study titled "Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma". The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with Multiple Myeloma who are relapsed after receiving prior treatment.
What is the current status of trial NCT00231166?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2005-09. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00231166?
The interventions under investigation include: HCD122 (DRUG).
Who is sponsoring clinical trial NCT00231166?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.